News articles about HTG Molecular Diagnostics (NASDAQ:HTGM) have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. HTG Molecular Diagnostics earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned media headlines about the medical research company an impact score of 46.981297786938 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:
- ValuEngine Lowers HTG Molecular Diagnostics (HTGM) to Strong Sell (americanbankingnews.com)
- HTG Molecular Diagnostics (HTGM) Upgraded to “Sell” at ValuEngine (americanbankingnews.com)
- Reviewing HTG Molecular Diagnostics (HTGM) & Mettler-Toledo International (MTD) (americanbankingnews.com)
- Head to Head Contrast: HTG Molecular Diagnostics (HTGM) vs. Bruker (BRKR) (americanbankingnews.com)
- HTG Announces New Patent for Its Technology Issued in Japan (finance.yahoo.com)
Shares of HTGM traded up $0.15 during mid-day trading on Monday, reaching $3.51. The company had a trading volume of 170,509 shares, compared to its average volume of 1,983,865. HTG Molecular Diagnostics has a twelve month low of $1.59 and a twelve month high of $7.68. The stock has a market cap of $95.28, a PE ratio of -1.94 and a beta of 1.63.
Several equities analysts have commented on HTGM shares. HC Wainwright set a $6.00 price target on HTG Molecular Diagnostics and gave the company a “buy” rating in a report on Wednesday, December 27th. Zacks Investment Research cut HTG Molecular Diagnostics from a “buy” rating to a “hold” rating in a report on Thursday, January 18th. Finally, Canaccord Genuity increased their target price on HTG Molecular Diagnostics to $5.00 in a report on Friday, January 5th. Two analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $6.56.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.